Endocrine Abstracts

Introduction: Homozygous familial hypercholesterolemia (HoFH) is a rare inherited autosomal dominant disease (1/20000 Individuals) involving germline mutations in the LDL metabolism pathways (LDL receptor/PCSK9/APOB/lDLRAP) that results in very high levels of LDLc, usually >10 mmol/l, and premature cardiovascular disease. The EAS guidelines recommend the use of PCSK9 inhibitors (PCSK9i) as a third line therapy in HoFH, however they report no precision regarding the effect ...